Sustained Viral Response in Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment
Sustained Viral Response in Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment
Chronic hepatitis B (CHB) is a serious liver disease worldwide, and the leading cause of
 cirrhosis and hepatocellular carcinoma (HCC). HBsAg loss/seroconversion is considered to be
 the ideal endpoint of antiviral therapy in both HBeAg-positive and -negative patients, and
 the ultimate treatment goal in CHB, However HBsAg loss occurred rarely by interferon
 treatment. Although It was reported that in nature history HBsAg level≤100 IU/ml can bring
 good long term outcomes in patients with chronic hepatitis B. it was not clear whether
 patients who achieved HBsAg level≤100 IU/ml by interferon treatment could maintain sustained
 viral response and the state of HBsAg level≤100 IU/ml.
The patients with chronic hepatitis B and achieved HBsAg level≤100 IU/ml after completed
 interferon treatment will be enrolled and observed for 96 weeks. Serum HBV DNA, HBsAg,
 anti-HBs, HBeAg, and anti-HBe will be measured every 3 months during the observation period,
 liver function tests were performed every 3 months also. The liver ultrasonic examination
 would be taken every 3-6 months. The primary endpoint is HBV DNA reaction. The secondary
 endpoints is HBsAg loss.
Inclusion Criteria:

 -  patients who had chronic hepatitis B and achieved HBsAg level≤100 IU/ml with
 undetectable HBV DNA level by interferon treatment

 Exclusion Criteria:

 -  Active consumption of alcohol and/or drugs

 -  Co-infection with human immunodeficiency virus, hepatitis C virus, or hepatitis D
 virus

 -  History of autoimmune hepatitis

 -  Psychiatric disease

 -  Evidence of neoplastic diseases of the liver